Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 9/2020

12.04.2020 | Brief Report

Relationship between faecal metronidazole and lactoferrin concentrations to clinical response of patients with Clostridioides difficile

verfasst von: Maria Saunders, Jinny Jeffery, Zoe Vincent, Ruth M. Ayling, Stephen Lewis

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We investigated patients with Clostridioides difficile-associated diarrhoea to see if clinical resolution correlated with faecal concentrations of metronidazole or markers of inflammation.

Methods

Faecal metronidazole, lactoferrin and serum CRP were measured daily. These were then compared with clinical progress.

Results

Metronidazole concentration correlated with lactoferrin (ρ = 0.17, p = 0.015), CRP (ρ = 0.23, p < 0.001) and number of diarrhoeal stools per day (ρ = 0.29, p < 0.001). Lactoferrin correlated with CRP (ρ = 0.57, p < 0.001) and the number of diarrhoeal stools per day (ρ = 0.52, p < 0.001) as did CRP (ρ = 0.52, p < 0.001).

Conclusions

We found no association between cessation of diarrhoea and metronidazole or lactoferrin concentrations. There was a relationship between metronidazole concentrations and markers of inflammation and stool frequency.
Literatur
1.
Zurück zum Zitat Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M (2014) Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 9:e106118CrossRef Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M (2014) Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 9:e106118CrossRef
2.
Zurück zum Zitat Wilcox MH (2013) Updated guidance on the management and treatment of Clostridium difficile infection. Public Health England 1–21 Wilcox MH (2013) Updated guidance on the management and treatment of Clostridium difficile infection. Public Health England 1–21
3.
Zurück zum Zitat Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME (2012) Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 40:1–8CrossRef Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME (2012) Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 40:1–8CrossRef
4.
Zurück zum Zitat Krook A, Lindström B, Kjellander J, Järnerot G, Bodin L (1981) Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol 34:645–650CrossRef Krook A, Lindström B, Kjellander J, Järnerot G, Bodin L (1981) Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol 34:645–650CrossRef
5.
Zurück zum Zitat D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC (2006) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Color Dis 22:429–427CrossRef D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC (2006) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Color Dis 22:429–427CrossRef
6.
Zurück zum Zitat Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit-time. Scand J Gastroenterol 32:920–924CrossRef Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit-time. Scand J Gastroenterol 32:920–924CrossRef
7.
Zurück zum Zitat Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW (2011) High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect 79:23–26CrossRef Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW (2011) High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect 79:23–26CrossRef
8.
Zurück zum Zitat Collin C, Wade DT, Davies S, Horne V (1988) The Barthel ADL Index: a reliability study. Int Disabil Stud 10:61–63CrossRef Collin C, Wade DT, Davies S, Horne V (1988) The Barthel ADL Index: a reliability study. Int Disabil Stud 10:61–63CrossRef
9.
Zurück zum Zitat Jeffery J, Vincent ZJ, Ayling RM, Lewis SJ (2017) Development and validation of a liquid chromatography tandem mass spectrometry assay for the measurement of faecal metronidazole. Clin Biochem 50:323–330CrossRef Jeffery J, Vincent ZJ, Ayling RM, Lewis SJ (2017) Development and validation of a liquid chromatography tandem mass spectrometry assay for the measurement of faecal metronidazole. Clin Biochem 50:323–330CrossRef
10.
Zurück zum Zitat Lewis SJ, Burmeister S, Brazier J (2005) Effect of the prebiotic oligofructose on relapse of Clostridium difficile associated diarrhoea: a randomised, controlled study. Clin Gastroenterol Hepatol 3:442–448CrossRef Lewis SJ, Burmeister S, Brazier J (2005) Effect of the prebiotic oligofructose on relapse of Clostridium difficile associated diarrhoea: a randomised, controlled study. Clin Gastroenterol Hepatol 3:442–448CrossRef
11.
Zurück zum Zitat Amon I, Amon K, Huller H (1978) Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol Biopharm 16:384–386PubMed Amon I, Amon K, Huller H (1978) Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol Biopharm 16:384–386PubMed
12.
Zurück zum Zitat Ralph ED, Clarke JT, Libke RD, Luthy RP, Kirby WM (1974) Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 6:691–696CrossRef Ralph ED, Clarke JT, Libke RD, Luthy RP, Kirby WM (1974) Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 6:691–696CrossRef
13.
Zurück zum Zitat Sadowska A, Kedra B, Cepowicz D, Rodziewicz L, Fiedorowicz A, Prokopiuk S, Miltyk W, Car H (2012) Increased concentration of metronidazole and its hydroxy metabolite in colon cancer in women. Pharmacol Rep 64:1276–1280CrossRef Sadowska A, Kedra B, Cepowicz D, Rodziewicz L, Fiedorowicz A, Prokopiuk S, Miltyk W, Car H (2012) Increased concentration of metronidazole and its hydroxy metabolite in colon cancer in women. Pharmacol Rep 64:1276–1280CrossRef
14.
Zurück zum Zitat Bergan T, Solhaug JH, Soreide O, Leinebo O (1985) Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol 20:945–950CrossRef Bergan T, Solhaug JH, Soreide O, Leinebo O (1985) Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol 20:945–950CrossRef
15.
Zurück zum Zitat Schneider MU, Riemann JF, Laudage G (1984) Serum concentrations of metronidazole and its main metabolite in patients with active Crohn’s disease: correlation with disease activity and therapeutic efficacy? Chemotherapy 30:345–352CrossRef Schneider MU, Riemann JF, Laudage G (1984) Serum concentrations of metronidazole and its main metabolite in patients with active Crohn’s disease: correlation with disease activity and therapeutic efficacy? Chemotherapy 30:345–352CrossRef
16.
Zurück zum Zitat Kelly CP, Kyne L (2011) The host immune response to Clostridium difficile. J Med Microbiol 60:1070–1079CrossRef Kelly CP, Kyne L (2011) The host immune response to Clostridium difficile. J Med Microbiol 60:1070–1079CrossRef
17.
Zurück zum Zitat El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB (2013) Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56:1713–1721CrossRef El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB (2013) Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56:1713–1721CrossRef
18.
Zurück zum Zitat Anikst VE, Gaur RL, Schroeder LF, Banaei N (2016) Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile. Diagn Microbiol Infect Dis 84:343–346CrossRef Anikst VE, Gaur RL, Schroeder LF, Banaei N (2016) Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile. Diagn Microbiol Infect Dis 84:343–346CrossRef
19.
Zurück zum Zitat Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert RE, Lyerly DM (2013) Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis 32:1517–1523CrossRef Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert RE, Lyerly DM (2013) Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis 32:1517–1523CrossRef
20.
Zurück zum Zitat Archbald-Pannone LR (2014) Quantitative fecal lactoferrin as a biomarker for severe Clostridium difficile infection in hospitalized patients. J Geriatr Palliat Care 2:3PubMedPubMedCentral Archbald-Pannone LR (2014) Quantitative fecal lactoferrin as a biomarker for severe Clostridium difficile infection in hospitalized patients. J Geriatr Palliat Care 2:3PubMedPubMedCentral
21.
Zurück zum Zitat He T, Kaplan SE, Gomez LA, Lu X, Ramanathan LV, Kamboj M, Tang YW (2018) Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 37:2341–2346CrossRef He T, Kaplan SE, Gomez LA, Lu X, Ramanathan LV, Kamboj M, Tang YW (2018) Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 37:2341–2346CrossRef
22.
Zurück zum Zitat Gallo A, Vallone C, Sabatelli L, Ventura G, Covino M, Cammarota G, Gasbarrini A, Landolfi R, Montalto M (2018) Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study. Scand J Gastroenterol 53:567–572CrossRef Gallo A, Vallone C, Sabatelli L, Ventura G, Covino M, Cammarota G, Gasbarrini A, Landolfi R, Montalto M (2018) Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study. Scand J Gastroenterol 53:567–572CrossRef
23.
Zurück zum Zitat Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, Jeong SH, Lee K (2017) Fecal calprotectin level reflects the severity of Clostridium difficile infection. Ann Lab Med 37:53–57CrossRef Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, Jeong SH, Lee K (2017) Fecal calprotectin level reflects the severity of Clostridium difficile infection. Ann Lab Med 37:53–57CrossRef
24.
Zurück zum Zitat Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG (2015) Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J Antimicrob Chemother 70:3061–3069CrossRef Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG (2015) Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J Antimicrob Chemother 70:3061–3069CrossRef
Metadaten
Titel
Relationship between faecal metronidazole and lactoferrin concentrations to clinical response of patients with Clostridioides difficile
verfasst von
Maria Saunders
Jinny Jeffery
Zoe Vincent
Ruth M. Ayling
Stephen Lewis
Publikationsdatum
12.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03895-8

Weitere Artikel der Ausgabe 9/2020

European Journal of Clinical Microbiology & Infectious Diseases 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.